Baseline characteristics in the SYNCHRONIZE™-2 randomized phase 3 trial of survodutide, a glucagon receptor/GLP-1 receptor dual agonist, for obesity in people with type 2 diabetes.
Quick Facts
What This Study Found
Key Numbers
How They Did This
Why This Research Matters
What This Study Doesn't Tell Us
Trust & Context
- Original Title:
- Baseline characteristics in the SYNCHRONIZE™-2 randomized phase 3 trial of survodutide, a glucagon receptor/GLP-1 receptor dual agonist, for obesity in people with type 2 diabetes.
- Published In:
- Diabetes, obesity & metabolism, 28(2), 1490-1498 (2026)
- Authors:
- Wharton, Sean(7), le Roux, Carel W(18), Bozkurt, Biykem(3), Platz, Elke, Bleckert, Gabriele, Ajaz Hussain, Samina, Brueckmann, Martina, Startseva, Elena, Kloer, Isabel M, Kaplan, Lee M
- Database ID:
- RPEP-16410
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-16410APA
Wharton, Sean; le Roux, Carel W; Bozkurt, Biykem; Platz, Elke; Bleckert, Gabriele; Ajaz Hussain, Samina; Brueckmann, Martina; Startseva, Elena; Kloer, Isabel M; Kaplan, Lee M. (2026). Baseline characteristics in the SYNCHRONIZE™-2 randomized phase 3 trial of survodutide, a glucagon receptor/GLP-1 receptor dual agonist, for obesity in people with type 2 diabetes.. Diabetes, obesity & metabolism, 28(2), 1490-1498. https://doi.org/10.1111/dom.70263
MLA
Wharton, Sean, et al. "Baseline characteristics in the SYNCHRONIZE™-2 randomized phase 3 trial of survodutide, a glucagon receptor/GLP-1 receptor dual agonist, for obesity in people with type 2 diabetes.." Diabetes, 2026. https://doi.org/10.1111/dom.70263
RethinkPeptides
RethinkPeptides Research Database. "Baseline characteristics in the SYNCHRONIZE™-2 randomized ph..." RPEP-16410. Retrieved from https://rethinkpeptides.com/research/wharton-2026-baseline-characteristics-in-the
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.